News
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 millionCARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients remaini ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback